Skip to main content
Egetis Therapeutics logo

Egetis Therapeutics — Investor Relations & Filings

Ticker · EGTX ISIN · SE0003815604 LEI · 549300RZCKGWRUBPMY22 ST Manufacturing
Open in API
Filings indexed 282 across all filing types
Latest filing 2021-05-17 Director's Dealing
Country SE Sweden
Listing ST EGTX

About Egetis Therapeutics

https://www.egetis.com/

Egetis Therapeutics is an innovative and integrated pharmaceutical company focused on developing and commercializing treatments for serious and rare diseases with significant unmet medical needs. The company's strategy centers on advancing drug candidates through late-stage clinical development to market approval. Its primary asset, Emcitate (tiratricol), is a first-in-class drug candidate in late-stage development for the treatment of Monocarboxylate Transporter 8 (MCT8) deficiency, a rare congenital disorder of thyroid hormone transport.

Recent filings

Filing Released Lang Actions
VD och ledande befattningshavare i Egetis Therapeutics förvärvar aktier
Director's Dealing Classification · 99% confidence The document is a press release titled "VD och ledande befattningshavare i Egetis Therapeutics förvärvar aktier" (CEO and senior executives in Egetis Therapeutics acquire shares). The core content details the purchase of company shares by the CEO, CFO, and VP of Commercial Operations. This type of filing, reporting personal share transactions by company directors and executives (insider trades), directly corresponds to the definition of Director's Dealing. Filing Type Code: DIRS (Director's Dealing). The document length (2812 chars) is short, but it is not announcing the publication of another report; it *is* the announcement itself regarding insider transactions.
2021-05-17 Swedish
Bulletin from Egetis Therapeutics’ Annual General Meeting 2021
AGM Information Classification · 100% confidence The document explicitly states it is a "Bulletin from Egetis Therapeutics' Annual General Meeting 2021". It details resolutions passed during the AGM, including the adoption of financial statements, election of board members, approval of remuneration, and stock option programs. This content directly corresponds to the definition of AGM Information.
2021-04-29 English
Kommuniké från Egetis Therapeutics årsstämma 2021
AGM Information Classification · 98% confidence The document title explicitly states "Kommuniké från Egetis Therapeutics årsstämma 2021" (Press release from Egetis Therapeutics Annual General Meeting 2021). The content details the decisions made during the AGM, such as the approval of financial statements, election of board members, approval of remuneration guidelines, and authorization for future share issues. This content directly relates to the proceedings and outcomes of the Annual General Meeting. Therefore, the appropriate classification is AGM Information (AGM-R). Although it is a press release summarizing the event, the core subject matter is the AGM itself, which takes precedence over a general RPA or RNS classification.
2021-04-29 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for the period January-March 2021. It contains comprehensive financial statements, key performance indicators (KPIs), management commentary, and updates on clinical trials (Emcitate, Aladote, PledOx). It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q1 2021
2021-04-22 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report January-March 2021' and contains comprehensive financial data, including a balance sheet, cash flow, and income statement comparisons for the period. It also includes detailed management commentary, project updates, and operational highlights. It meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. Q1 2021
2021-04-22 English
Egetis Therapeutics appoints Yilmaz Mahshid as new CFO
Board/Management Information Classification · 99% confidence The document is a press release announcing a specific personnel change: the appointment of a new Chief Financial Officer (CFO), Yilmaz Mahshid. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of 'Board/Management Information' (MANG). The document is short and focused solely on this management transition, not a full financial report (like 10-K or IR) or a general regulatory filing (RNS).
2021-04-19 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.